CMC to Expand Under US Ownership

CMC Biologics A/S recently fetched EUR 25 million from a US capital fund which is to take over the leadership in the company from BankInvest. CMC Biologics will now have financial strength to consolidate the market for active pharmaceutical ingredients through the support from a new US investor. CMC already ranks in the top four and is growing faster than the market. However, the new investor, which will have the majority on the board continue to expand through acquisitions based on the Danish company. The US capital fund Monitor Clipper will have an owner share of approximately 50 per cent of CMC which on the other hand will have a capital injection of EUR 25 million to be employed in expanding the capacity in the manufacturing facilities of ICOS Biologics that the company recently acquired.

For further information please contact:

Mads Laustsen,

CEO

Tel: +45 29 48 84 01

Email: info@cmcbio.com

Or visit: www.cmcbio.com